Verapamil SR

Phase 2Small molecule

MMedical University of Graz

Verapamil SR is one of 20 small molecule programs targeting Type 1 Diabetes. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Type 1 DiabetesActive, not recruiting

Type 1 DiabetesPhase 2

Active, not recruiting

Competition

Competitive Landscape

384 competitors in Type 1 Diabetes

#DrugCompanyPhaseTrials

Symlin

AstraZeneca

Preclinical

3 2

Aldomet

Neurocrine Biosciences

Preclinical

2 3

Glargine

Eli Lilly

Preclinical

4 4

Pitocin

RRetrophin

Preclinical

1 5

Feraheme

AAzurity Pharmaceuticals

Preclinical

1 6

Cytoxan

BBaxter Healthcare Corporation

Preclinical

1 7

Foradil

Viatris

Preclinical

1 8

SGLT2 Inhibitor

Eli Lilly

Preclinical

1 9

Verapamil SR

MMedical University of Graz

Phase 2

1 10

Teplizumab

Sanofi

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Type 1 Diabetes1 trial

Verapamil SR in Adults With Type 1 Diabetes

Active, not recruiting·MMedical University of Graz·Phase 2·NCT04545151·138 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Verapamil SR. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Verapamil SR compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Verapamil SR. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Medical University of Graz company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: MMedical University of Graz

Verapamil SR

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Type 1 Diabetes1 trial

References

Drug Info

Quick Facts

Related News